Human hepatocellular carcinoma cells (HCC cells)

Human hepatocellular carcinoma (HCC) cells are malignant hepatocytes that constitute the primary form of liver cancer, typically arising in the context of chronic liver disease or cirrhosis [2, 17]. These cells are characterized by a complex genomic landscape and the dysregulation of multiple signaling pathways, including those involved in cell growth (Raf/MEK/ERK), survival (PI3K/Akt/mTOR), and angiogenesis (VEGF/VEGFR) [2, 11]. While HCC cells themselves are not a single molecular target, they harbor numerous proteins—such as receptor tyrosine kinases and immune checkpoint ligands—that are the focus of modern systemic therapies [1, 8]. Therapeutic approaches often utilize multikinase inhibitors like sorafenib or combination immunotherapies such as atezolizumab and bevacizumab to inhibit tumor proliferation and modify the immunosuppressive microenvironment [1, 4]. However, treatment remains challenging due to significant tumor heterogeneity and the frequent presence of underlying liver dysfunction, which impacts the safety and efficacy of therapeutic interventions [14, 17].

Other names

Hepatoma cellsLiver cancer cellsMalignant hepatocytesHCC

Multi-kinase inhibition (targeting VEGFR, PDGFR, FGFR, and Raf), immune checkpoint inhibition (PD-1/PD-L1 and CTLA-4), and VEGF neutralization to inhibit tumor proliferation and angiogenesis [1, 2, 4, 8].